Stockscreener 앱 받기
0.335
0.60%
0.002
시간 외 거래:
.33
-0.005
-1.49%
전일 마감가:
$0.333
열려 있는:
$0.339
하루 거래량:
116.88K
Relative Volume:
1.29
시가총액:
$4.83M
수익:
$389.00K
순이익/손실:
$-13.13M
주가수익비율:
-0.3245
EPS:
-1.0323
순현금흐름:
$-11.90M
1주 성능:
-9.70%
1개월 성능:
-23.83%
6개월 성능:
-78.10%
1년 성능:
-79.70%
1일 변동 폭
$0.326
$0.3714
1주일 범위
$0.305
$0.42
52주 변동 폭
$0.2711
$3.2324
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Compare CLGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
0.335 | 4.80M | 389.00K | -13.13M | -11.90M | -1.0323 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-02-17 | 개시 | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd 주식(CLGN)의 최신 뉴스
CollPlant Heads Toward Nasdaq Deadline With Stock at 40 Cents - Bez Kabli
CollPlant Biotechnologies (CLGN) Holds Near Support Amidst Modest Downside PressureBear Flag - newsline.com
Deal Dispatch: Fertitta Entertainment Buys Caesars For $17.6 Billion, Arsenal Capital Buys Velcro Brands, Teaneck Surgical Center Bankruptcy - Sahm
CollPlant Biotechnologies Posts Wider Q1 Loss as It Explores Strategic Alternatives and Advances Regenerative Aesthetics Pipeline - The Globe and Mail
CollPlant Biotechnologies (CLGN) Hovers Near Support at $0.38 After Marginal DeclineTrend Continuation Trade - The Legal Advocate
Deal Dispatch: Fertitta Entertainment Buys Caesars For $17.6 Billion, Arsenal Capital Buys Velcro Brands, Teaneck Surgical Center Bankruptcy - Benzinga
CollPlant (CLGN) Reports Q1 2026 Financials and Strategic Updates - GuruFocus
CollPlant Q1 revenue falls to $73K, initiates strategic review - grafa.com
Collplant Biotechnologies: No Definitive Timetable for Process >CLGN - Moomoo
Collplant Biotechnologies: Initiates Process to Evaluate Strategic Alternatives Aimed at Maximizing Shareholder Value >CLGN - Moomoo
Collplant Biotechnologies 1Q Loss $3.1M >CLGN - Moomoo
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PR Newswire
CollPlant Biotechnologies (CLGN) Slips Slightly as Stock Tests Key Support near $0.40ATR Stop - The League of Women Voters of Texas
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Quantisnow
CLGN Q4 2025 Earnings: Miss on EPS as Pre-Revenue Biotech Advances PipelineViral Trade Signals - Newser
CLGN Q1'26 Earnings: revenue estimate is 460.00K USD - TradingView
TradingKey - TradingKey
D. Boral Capital Maintains CollPlant Biotechnologies (CLGN) Buy Recommendation - MSN
CLGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Hugh M. Evans (CLGN) details CollPlant share, RSU and option holdings - Stock Titan
[EFFECT] CollPlant Biotechnologies Ltd SEC Filing - Stock Titan
CollPlant (CLGN) registers 3.296M shares for resale; warrants convertible into shares - Stock Titan
CollPlant (CLGN) Stock: Investment Potential Insight (Climbs) 2026-04-20Social Buzz Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Jasmine Seror Net Worth (2026) - GuruFocus
Avraham Havron Net Worth (2026) - GuruFocus
Elan Penn Net Worth (2026) - GuruFocus
Bowman Bagley Net Worth (2026) - GuruFocus
Bar Berta Abelis Net Worth (2026) - GuruFocus
Eran Rotem Net Worth (2026) - GuruFocus
Oren Fahimipoor Net Worth (2026) - GuruFocus
Philippe Bensimon Net Worth (2026) - GuruFocus
Yehiel Tal Net Worth (2026) - GuruFocus
CollPlant (NASDAQ: CLGN) registers 3.296M resale shares; warrants detail - Stock Titan
CLGN SEC FilingsCollplant Biotechnologies Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Momentum Shift: Can CollPlant Biotechnologies Ltd sustain earnings growthGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
CollPlant implementing cost-reduction and workforce optimization plan - TipRanks
CLGN Implements Major Cost-Cutting Measures for Future Growth - GuruFocus
CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead - Intellectia AI
CollPlant Resets Strategy After AbbVie Ends Filler Deal, Slashes Workforce by 50% - TipRanks
CollPlant ends AbbVie deal, cuts workforce by 50% By Investing.com - Investing.com South Africa
CollPlant announces termination of development agreement with AbbVie - TipRanks
AbbVie ends CollPlant (NASDAQ: CLGN) filler pact as CollPlant slashes workforce 50% - Stock Titan
CollPlant Biotechnologies Ltd and Allergan Industrie SAS Terminate Development Agreement - marketscreener.com
CollPlant Issues Letter to Shareholders (2026-04-13) - Seeking Alpha
Buyback Watch: Does CollPlant Biotechnologies Ltd stock have upside surprise potentialCEO Change & Capital Protection Trading Alerts - baoquankhu1.vn
Is CollPlant (CLGN) Stock in a Selling Zone | Price at $0.41, Up 6.77%Dealer Positioning - newsline.com
Aug Swings: What is CollPlant Biotechnologies Ltds debt to equity ratioEarnings Recap Summary & High Return Trade Guides - baoquankhu1.vn
Will CollPlant (CLGN) Stock Outperform S&P 500 | Price at $0.50, Down 5.48%Bear Pennant - The Legal Advocate
CLGN Stock Analysis: CollPlant Biotechnologies 0.53 Daily Dip Performance Update - The Legal Advocate
CollPlant Files to Sell 3.3M Ordinary Shares - Intellectia AI
Collplant Biotechnologies Ltd (CLGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):